We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04661176
Previous Study | Return to List | Next Study

Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04661176
Recruitment Status : Active, not recruiting
First Posted : December 10, 2020
Last Update Posted : September 14, 2022
Sponsor:
Information provided by (Responsible Party):
miR Scientific LLC

Brief Summary:

The miR Scientific Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) is a new molecular assay that interrogates 442 small non-coding RNAs extracted from urinary exosomes and provides urologists an early, very precise indication of disease status in men presenting with suspicion of prostate cancer. The assay classifies the disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk of aggressive, potentially lethal prostate cancer.

The primary objective of this study is to assess the clarity of explanation of the biological background and clinical impact of the Sentinel™ PCC4 Assay, and the comfort level of urologists with the clinical data and report form, including the ease of understanding of results, and the potential use in clinical management of prostate cancer.

Men being seen by urologists in the course of their normal practice, presenting with suspicion of prostate cancer (based on DRE and/or elevated Prostate Specific Antigen (PSA)) and scheduled for core-needle biopsy will be asked to consent to the clinical study and provide one or more 50 mL sample of non-DRE urine along with relevant anonymized clinical data with the study team. The urine samples will be shipped to miR Scientific laboratories in Rensselaer NY, for exosomal sncRNA extraction and interrogation. The molecular status of the participant will be reported as a Sentinel™ PCC4 Risk Level.

The second primary objective of this study is to establish the performance characteristics of the Sentinel™ PCC4 Assay in the Puerto Rican population for identifying men with NMEPC, and men with evidence of high-risk prostate cancer.

Participants will receive the standard of care (SOC), including measurement of PSA, DRE and TRUS-guided systematic or MRI-guided targeted biopsy. Based on the histopathology report of the core-needle biopsy, read by pathologists associated with local institution, participants with no positive cores will be designated "cancer-free"; otherwise patients with cancer in one or more cores will have the clinical data associated with the SOC collected (including the Gleason grade group, tumor staging, PSA, race and CAPRA risk assessment score). The CAPRA score will be compared to the molecular classification provided by the Sentinel™ PCC4 Assay.


Condition or disease Intervention/treatment
Prostate Cancer Diagnostic Test: miR Sentinel™ PCC4 Assay

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Evaluation of the Training Plan and Impact on Acceptance of the Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) and Determination of Assay Performance Characteristics of Clinical Utility in a Puerto Rican Population
Actual Study Start Date : November 30, 2020
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer


Intervention Details:
  • Diagnostic Test: miR Sentinel™ PCC4 Assay
    This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.


Primary Outcome Measures :
  1. Acceptability of the Sentinel™ PCC4 Assay for physicians assessing the prostate health in men [ Time Frame: 1 month after the intial 200 participants are accrued, and when 350 and 500 participants have been accrued. ]
    To assess the acceptability of the miR Scientific Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) for physicians assessing the prostate health of men presenting with suspicion of prostate cancer including, but not limited to elevated serum Prostate Specific Antigen (PSA) level, suspicious DRE, family history of prostate cancer or germline mutation. The Sentinel™ PCC4 Assay is a urine exosome-based diagnostic/prognostic assay that identifies patients with no prostate cancer and classifies patients with prostate cancer into low, intermediate or high-risk disease.

  2. Validate the performance characteristics of the Sentinel™ PCC4 Assay in men in Puerto Rico [ Time Frame: 72 hours post sample receipt, urinary exosomal RNA samples will be extracted and analyzed using the Sentinel™ PCC4 Assay ]
    Using the data collected as part of the primary study objective #1 to establish and validate the performance characteristics of the Sentinel™ PCC4 Assay in men in Puerto Rico.


Biospecimen Retention:   Samples Without DNA
Urine (one or more 50 mL samples) for Sentinel™ PCC4 Assay where urinary exosomal RNA will be extracted and retained for study analysis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Must be male to screen for prostate cancer
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A total of up to 500 male subjects will be enrolled from multiple clinical sites in Puerto Rico. Subjects will be men older than 22 with a core needle biopsy as part of routine clinical workup for initial diagnosis of prostate cancer.
Criteria

Inclusion Criteria:

  1. Males with suspicion of prostate cancer including, but not limited to elevated PSA level, suspicious DRE, family history of prostate cancer, and/or germline mutation.
  2. Signed informed consent prior to initiation of any study-related procedures.
  3. Minorities are included in this protocol.
  4. The patient provided a urine sample within 30 days prior to biopsy being performed.
  5. Patients who sign the consent form, but after shared decision making discussions with their urologist decide not to undergo a core needle biopsy. Since these may represent up to 5% of patients and represent the current SOC, these patients will be separately categorized as "Prostate Biopsy Declined" (PBD).

Exclusion Criteria:

  1. Persons younger than 22 years of age. Since patients with germline mutations and/or family history may want to be screened before the age of 45 (as recommended by the NCCN) and some men over the age of 75 individuals may request a diagnostic core needle biopsy after shared decision making with their urologist, we have chosen not to include an age range that may exclude these individuals. The lower age limit is designed to exclude children from the study.
  2. Persons incapable of providing informed consent.
  3. Persons presenting with clinical symptoms of urinary tract infection, including prostatitis at the time of enrollment.
  4. Persons with prior history of invasive treatment for benign prostatic hyperplasia within 3- 6 months of study enrollment.
  5. Patients treated with finasteride or bicalutamide for BPH or male pattern baldness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04661176


Locations
Layout table for location information
Puerto Rico
San Juan Bautista School of Medicine Clinical Research Unit
Caguas, Puerto Rico, 00725
Hospital Menonita de Caguas
Caguas, Puerto Rico, 00726
Hospital Metropolitano Dr. Pila
Ponce, Puerto Rico, 00717
Sponsors and Collaborators
miR Scientific LLC
Investigators
Layout table for investigator information
Principal Investigator: Alvin Lopez-Pujals, MD San Juan Bautista School of Medicine Clinical Research Unit
Layout table for additonal information
Responsible Party: miR Scientific LLC
ClinicalTrials.gov Identifier: NCT04661176    
Other Study ID Numbers: MIR-P003
First Posted: December 10, 2020    Key Record Dates
Last Update Posted: September 14, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by miR Scientific LLC:
Diagnosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases